261 related articles for article (PubMed ID: 8820944)
1. Resistance mechanisms to methotrexate in tumors.
Bertino JR; Göker E; Gorlick R; Li WW; Banerjee D
Stem Cells; 1996 Jan; 14(1):5-9. PubMed ID: 8820944
[TBL] [Abstract][Full Text] [Related]
2. Resistance Mechanisms to Methotrexate in Tumors.
Bertino JR; Göker E; Gorlick R; Li WW; Banerjee D
Oncologist; 1996; 1(4):223-226. PubMed ID: 10387992
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of resistance to antifolates, a review.
Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
[TBL] [Abstract][Full Text] [Related]
4. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
5. Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.
McGuire JJ; Haile WH; Russell CA; Galvin JM; Shane B
Oncol Res; 1995; 7(10-11):535-43. PubMed ID: 8866666
[TBL] [Abstract][Full Text] [Related]
6. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application.
McIvor RS
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S50-4. PubMed ID: 8971409
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of methotrexate resistance in osteosarcoma.
Guo W; Healey JH; Meyers PA; Ladanyi M; Huvos AG; Bertino JR; Gorlick R
Clin Cancer Res; 1999 Mar; 5(3):621-7. PubMed ID: 10100715
[TBL] [Abstract][Full Text] [Related]
8. [Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].
Chen J; Gu LJ; Ying DM; Shen M; Wu HJ
Ai Zheng; 2002 Dec; 21(12):1335-40. PubMed ID: 12520743
[TBL] [Abstract][Full Text] [Related]
9. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene.
Takebe N; Zhao SC; Adhikari D; Mineishi S; Sadelain M; Hilton J; Colvin M; Banerjee D; Bertino JR
Mol Ther; 2001 Jan; 3(1):88-96. PubMed ID: 11162315
[TBL] [Abstract][Full Text] [Related]
10. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
Goldman ID; Matherly LH
NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic heterogeneity in cultured human head and neck squamous cell carcinoma lines with low-level methotrexate resistance.
Rosowsky A; Wright JE; Cucchi CA; Lippke JA; Tantravahi R; Ervin TJ; Frei E
Cancer Res; 1985 Dec; 45(12 Pt 1):6205-12. PubMed ID: 2415240
[TBL] [Abstract][Full Text] [Related]
12. [Methotrexate and its drug resistance].
Nagura E
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2882-7. PubMed ID: 3178237
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
14. Investigations on the mechanisms of methotrexate resistance in a cisplatin-resistant L1210 murine leukemia cell subline.
Wroblewski DH; Bhushan A; Xuan Y; Brinton BT; Tritton TR; Hacker MP
Cancer Chemother Pharmacol; 1996; 37(4):337-42. PubMed ID: 8548879
[TBL] [Abstract][Full Text] [Related]
15. Design and rationale for novel antifolates.
Bertino JR; Sobrero A; Mini E; Moroson BA; Cashmore A
NCI Monogr; 1987; (5):87-91. PubMed ID: 3431593
[TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
McGuire JJ; Magee KJ; Russell CA; Canestrari JM
Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
18. A comparison of dihydrofolate reductase activity in intact leukemia cells and squamous cell carcinoma.
FitzGerald GB; Wick MM
Anticancer Drug Des; 1989 Jun; 4(1):79-87. PubMed ID: 2757754
[TBL] [Abstract][Full Text] [Related]
19. Rates of development of methotrexate resistance in heterogeneous mouse mammary tumor cell cultures.
Miller BE; Matherly LH; Lehotan M; Heppner GH
J Exp Ther Oncol; 1996 Jan; 1(1):30-8. PubMed ID: 9414386
[TBL] [Abstract][Full Text] [Related]
20. Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells.
Chu BC; Fan CC; Howell SB
J Natl Cancer Inst; 1981 Jan; 66(1):121-4. PubMed ID: 6935452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
